Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105; email:
Annu Rev Pathol. 2015;10:547-62. doi: 10.1146/annurev-pathol-012414-040259.
Retinoblastoma is a pediatric tumor of the developing retina from which the genetic basis for cancer development was first described. Inactivation of both copies of the RB1 gene is the predominant initiating genetic lesion in retinoblastoma and is rate limiting for tumorigenesis. Recent whole-genome sequencing of retinoblastoma uncovered a tumor that had no coding-region mutations or focal chromosomal lesions other than in the RB1 gene, shifting the paradigm in the field. The retinoblastoma genome can be very stable; therefore, epigenetic deregulation of tumor-promoting pathways is required for tumorigenesis. This review highlights the genetic and epigenetic changes in retinoblastoma that have been reported, with special emphasis on recent whole-genome sequencing and epigenetic analyses that have identified novel candidate genes as potential therapeutic targets.
视网膜母细胞瘤是一种发生于发育中视网膜的小儿肿瘤,其癌症发展的遗传基础最初就是在此被描述的。RB1 基因的两个拷贝失活是视网膜母细胞瘤中主要的起始遗传病变,也是肿瘤发生的限速步骤。最近对视网膜母细胞瘤的全基因组测序揭示了一种肿瘤,除了 RB1 基因之外,没有编码区突变或局灶性染色体病变,这一发现改变了该领域的范式。视网膜母细胞瘤的基因组可以非常稳定;因此,肿瘤促进途径的表观遗传失调是肿瘤发生所必需的。本综述强调了已报道的视网膜母细胞瘤中的遗传和表观遗传变化,特别强调了最近的全基因组测序和表观遗传分析,这些分析确定了新的候选基因作为潜在的治疗靶点。